<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512574</url>
  </required_header>
  <id_info>
    <org_study_id>WonkwangUH5</org_study_id>
    <nct_id>NCT03512574</nct_id>
  </id_info>
  <brief_title>Combination Effects of Pregabalin and Dexmedetomidine on Postoperative Pain</brief_title>
  <official_title>The Effect of the Combination of Pregabalin and Dexmedetomidine on the Management of Postoperative Pain in Patients Undergoing Total Knee Arthroplasty (TKA) or Total Hip Arthroplasty (THA) Under Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wonkwang University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wonkwang University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregabalin and dexmedetomidine have been introduced to manage postoperative pain. The present
      study aimed to evaluate the effect of the combination of two drugs on pain relief in patients
      undergoing total knee or hip arthroplasty under spinal anesthesia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred and twenty-four patients undergoing total knee or hip arthroplasty under spinal
      anesthesia were randomly assigned to either group C (n = 31, placebo), group P (n = 33,
      pregabalin), group PD (n = 29, pregabalin and dexmedetomidine) or group D (n = 31,
      dexmedetomidine). One hour before spinal anesthesia, patients received pregabalin 150 mg or
      placebo orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before
      induction of spinal anesthesia, followed by a continuous infusion of 0.5 μg/kg/hr or the same
      calculated volume of normal saline till completion of the surgery. Clinically relevant pain
      for 24 h after surgery including time to first analgesic request visual analog scale (VAS),
      ketorolac dose, and patient controlled analgesics (PCA) volume consumed were recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient controlled analgesics (PCA) volume</measure>
    <time_frame>For 24 hours</time_frame>
    <description>Patient controlled analgesics (PCA) volume consumed for 24 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to first analgesic request</measure>
    <time_frame>for 24 hours</time_frame>
    <description>time to first analgesic request for 24 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analog scale (VAS)</measure>
    <time_frame>for 24 hours</time_frame>
    <description>The VAS consisted of a straight line with the left end of the line representing no pain and the right end of the line representing the worst pain. Patients were asked to mark the position on the line corresponding to their perception of pain. The VAS scores for pain at rest and on movement were measured at intervals of 24, and 48 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ketorolac dose</measure>
    <time_frame>for 24 hours</time_frame>
    <description>ketorolac dose for 24 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>within the first 24 hours postoperatively</time_frame>
    <description>Perioperative adverse effects Shivering, blurred vision, headache, dizziness, dry mouth, nausea/vomiting during the first 24 hours postoperatively</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Group PD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of pregabalin and dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pregabalin +placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo + dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery</description>
    <arm_group_label>Group P</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin and dexmedetomidine</intervention_name>
    <description>One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.</description>
    <arm_group_label>Group PD</arm_group_label>
    <other_name>study drugs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II

          -  Aged 18-75 years

        One hundred and twenty-four patients with intact cognitive function to understand this
        study undergoing elective total knee or hip arthroplasty under spinal anesthesia

        Exclusion Criteria:

          -  Pregnant

          -  Allergic and/or contraindicated to the study drugs

          -  American Society of Anesthesiologists (ASA) score III and above

          -  Having drug

          -  Alcohol addiction

          -  Renal failure

          -  Diabetes mellitus

          -  Epilepsy

          -  currently using opioids for chronic pain and/or any of the drugs studied.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilho Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonkwang University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WonwangUH</name>
      <address>
        <city>Iksan</city>
        <state>Jeonbuk</state>
        <zip>570-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2018</study_first_submitted>
  <study_first_submitted_qc>April 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>April 29, 2018</last_update_submitted>
  <last_update_submitted_qc>April 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wonkwang University Hospital</investigator_affiliation>
    <investigator_full_name>Cheol Lee</investigator_full_name>
    <investigator_title>Professor,M.D.,Ph.D</investigator_title>
  </responsible_party>
  <keyword>pregabalin, dexmedetomidine, postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

